title: Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants.
abstract: We have evaluated the effects of the different components of hormone replacement therapy (HRT) on the production of free radicals in platelet membranes from menopausal women. The study included 12 women in menopause for at least 6 months to a maximum of 4 years. First, the effect was determined of progestin only during the administration of 20 mg/day medroxyprogesterone acetate for 5 days. The peroxide production level was measured on day 0 and day 5. The second set of experiments was carried out in the first month of cyclic HRT with transdermal estradiol 50 micrograms/day from day 1 to day 25 and medroxy-progesterone acetate from day 13 to day 25. In this experiment, the peroxide level was evaluated on days 0, 12 and 25. A significant reduction of peroxide level was observed after oral medroxyprogesterone acetate administration. During HRT, we observed a similar reduction in lipid oxidation at the peak of the estrogen effect, and a further decrease with the administration of medroxyprogesterone acetate. It is concluded that reduction of lipid peroxidation during HRT is not only due to estrogens, but also depends upon the combined action of sex steroids. This observation justifies not only the combined regimen (estrogens plus progestin) in HRT, but also the positive effects of progestins alone on patients who cannot use estrogens.
authors.affiliation: Department of Obstetrics and Gynecology, University of Ancona, Italy.
authors.forename: A L
authors.initials: AL
authors.lastname: Tranquilli
authors.forename: L
authors.initials: L
authors.lastname: Mazzanti
authors.forename: A M
authors.initials: AM
authors.lastname: Cugini
authors.forename: N
authors.initials: N
authors.lastname: Cester
authors.forename: G G
authors.initials: GG
authors.lastname: Garzetti
authors.forename: C
authors.initials: C
authors.lastname: Romanini
mesh_terms: D000279:Administration, Cutaneous; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism / Q000648:ultrastructure; D002462:Cell Membrane / Q000378:metabolism / Q000648:ultrastructure; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000592:standards*; D005260:Female; D005609:Free Radicals; D006801:Humans; D015227:Lipid Peroxidation; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D008563:Membrane Lipids / Q000378:metabolism; D008875:Middle Aged; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000627:therapeutic use*; D011372:Progestins / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D005609:Free Radicals; D008563:Membrane Lipids; D045167:Progesterone Congeners; D011372:Progestins; D004958:Estradiol; D017258:Medroxyprogesterone Acetate